Shohei Koide, Ph.D. – Professor, Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, and Director, Cancer Biologics, Perlmutter Cancer Center, NYU Langone Health

Shohei Koide, Ph.D., is a Professor of Biologics Design in the Department of Biochemistry and Molecular Pharmacology at the New York University (NYU) Grossman School of Medicine and the Director of Cancer Biologics at the Perlmutter Cancer Center at NYU Langone Health. He is a Fellow of the American Association for the Advancement of Science.

A leader in the field of protein engineering and design, Dr. Koide’s research integrates rational design, directed evolution, structural biology, and cell biology to design highly functional, but still simple, antibodies and other types of target-binding proteins, and applies such synthetic binding proteins as therapeutics and research tools. Dr. Koide is the inventor of the FN3 monobody technology, a widely adopted non-antibody scaffold system, and has established it as an enabling technology for addressing fundamental challenges in chemical, structural, and cellular biology. His current research focuses on the discovery of biologics therapeutics and strategies to control ‘undruggable’ targets.

Previously, Dr. Koide was a Professor of Biochemistry and Molecular Biology at the University of Chicago and served as a scientific co-director of the Chicago Biomedical Consortium. Dr. Koide has published more than 130 peer-reviewed articles and is the inventor of several patent families. He earned his Ph.D., M.S., and B.Sc. degrees from the University of Tokyo, and he was a Human Frontier Science Program Postdoctoral Fellow in Molecular Biophysics at The Scripps Research Institute in La Jolla, CA.


George Trainor, Ph.D. - Former head of Chemistry, Bristol Myers Squibb

Dr. Trainor brings 30 years of experience in the Biotechnology and Pharmaceutical Industries. He has expertise in overall drug discovery strategy and execution, medicinal chemistry, and the application of transformative technologies. Leading teams of over 100 scientists, he has advanced over 35 drug candidates into clinical development in a diverse spectrum of therapeutic areas including antivirals, cancer, neuroscience, and inflammation. His team provided key discovery support that enabled the successful launch of SustivaTM for HIV disease.

Dr. Trainor is a partner at BioMotiv which he joined after leaving Bristol Myers Squibb Company as Vice President of Oncology and Early Discovery Chemistry. At BMS George was responsible for all aspects of medicinal chemistry for the oncology area as well as hit-to-leads activities in support of all therapeutic areas. Prior to being merged into Bristol Myers Squibb, Dr. Trainor was Executive Director for Medicinal Chemistry at Dupont/Dupont Merck Pharmaceuticals. His key contribution from that period was the discovery and commercial development of fluorescence-tagged chain terminators for use in automated DNA sequencing. This breakthrough technology was subsequently employed in the sequencing of the human genome, and In 2011, Trainor won the American Chemical Society’s Heroes of Chemistry Award for his work on DNA sequencing.  Dr. Trainor did his undergraduate work at Stevens Institute of Technology, received his PhD in Organic Chemistry at Harvard University, and was an NIH Postdoctoral Fellow at Columbia University.

paul workman

Paul Workman, Ph.D. – Chief Executive and President of The Institute of Cancer Research, London

Paul Workman, Ph.D., is Chief Executive and President of The Institute of Cancer Research (ICR), London, and is the Harrap Professor of Pharmacology and Therapeutics at the ICR. He is a Fellow of the Royal Society (the UK’s national academy of science), Academy of Medical Sciences, Royal Society of Chemistry, Royal Society of Biology, Royal Society of Medicine, and the European Academy Cancer Sciences. He is also a Cancer Research UK (CRUK) Life Fellow.

A leader in the field of molecularly targeted cancer drugs, Dr. Workman’s research focus is the discovery and development of cancer drugs that exploit our knowledge of the cancer genome and cancer biology, toward the goal of personalized medicine. He has been instrumental in the discovery of more than 20 new molecularly targeted anticancer drug candidates. Dr. Workman is especially renowned for his innovative personal research in the discovery, chemical biology, and molecular pharmacology of leading drugs acting on protein kinases, PI3 kinases and the molecular chaperone HSP90, and he is the originator of the widely used Pharmacologic Audit Trail for biomarker-led drug development.

Throughout his career, Dr. Workman has worked at the interface of biology, chemistry, and medicine and he was the Founding Director of the CRUK Convergence Centre at ICR and Imperial College, London – focusing on the application of engineering and physical sciences to cancer research and treatment. He has a major interest in the discovery and application of chemical probes in biomedical research and was instrumental in the creation and development of free web resources for chemical tools, drug discovery, and translational research – namely the Chemical Probes Portal, canSAR, and Probe Miner.

From 1997 to January 2016, Dr. Workman was the Director of the Cancer Research UK Cancer Therapeutics Unit at the ICR – the largest academic cancer drug discovery center worldwide. Previously, Dr. Workman spent four years in the cancer drug discovery leadership team at AstraZeneca, and prior to that worked at Glasgow, Stanford, and Cambridge Universities. Dr. Workman obtained his B.Sc. in Biological Sciences from the University of Leicester, UK, and his Ph.D. in Cancer Pharmacology from the University of Leeds, UK. In addition, Dr. Workman was a scientific founder of Piramed Pharma (acquired by Roche) and Chroma Therapeutics.

Dr. Workman has published more than 500 scientific articles, receiving over 45,000 citations, with an h-index of 111. He has received numerous honors and awards, including the Royal Society of Chemistry George and Christine Sosnovsky Award for Cancer Therapy, Royal Society of Chemistry World Entrepreneur Award, CRUK Translational Cancer Research Prize, and the International Raymond Bourgine Award for Excellence in Cancer Research. Dr. Workman led the team that won the 2012 American Association of Cancer Research Team Science Award, and under his leadership the ICR was awarded a 2017 Queens’ Anniversary Prize for its world-leading research in cancer drug discovery leading to global patient impact. He writes and blogs about cancer research and drug discovery.